Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 9, 2004, Pages 901-910

  Minghetti, Luisa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Brain inflammation; Cyclooxygenase (COX); Neurodegeneration; Neuroprotection; Non steroidal anti inflammatory drugs (NSAIDs); Prostaglandin

Indexed keywords

ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GROWTH FACTOR; IBUPROFEN; INDOMETACIN; ISOENZYME; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARACHIDONIC ACID METABOLISM; BEHAVIOR; BRAIN DEGENERATION; BRAIN FUNCTION; CATALYSIS; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; COGNITION; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DRUG TARGETING; ENCEPHALITIS; ENZYME INDUCTION; HUMAN; INFLAMMATION; MICROGLIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW;

EID: 4444333049     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.9.901     Document Type: Review

References (74)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-35
2. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271: 33157-60
3. Marshall PJ, Kulmacz RJ, Lands WEM. Constraints of prostaglandin biosynthesis in tissues. J Biol Chem 1987;262:3510-17
4. Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharm Exp Ther 2002;300:367-75
5. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-48
6. Yamagata K, Andreasson KI, Kaufmann WE., Barnes CA, Worley PE Expression of a mitogen-inducible cyclooxygense in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-86
7. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995;355:296-315
8. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-60
9. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999;830:226-36
10. Graham SH, Hickey RW. Cyclooxygenases in central nervous system diseases: A special role for cyclooxygenase 2 in neuronal cell death. Arch Neurol 2003;60:628-30
11. Schwab JM, Schluesener HJ. Cyclooxygenases and central nervous system inflammation: Conceptual neglect of cyclooxygenase 1. Arch Neurol 2003;60:630-32
12. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cycloxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: Cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926-31
13. Shaftel SS, Olschowka JA, Hurley SD, Moore AH, O'Banion MK. COX-3: A splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res Mol Brain Res 2003;119:213-15
14. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997;54:601-24
15. Minghetti L, Levi G. Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Prog Neurobiol 1998;54:99-125
16. O'Banion MR. Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Crit Rev Neurobiol 1999;13:45-82
17. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-21
18. Kaufmann WE, Worley PF, Taylor CV, Bremer M, Isakson PC. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev 1997;19:25-34
19. Riccieri L, Minghetti L, Moles A, et al. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinegic hypofunction in rats. Exp Neurol 2004; in press.
20. Teather LA, Packard MG, Bazan NG. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem 2002;9:41-47
21. Holscher C. Inhibitors of cyclooxygenase produce amnesia for passive avoidance task in the chick. Eur J Neurosci 1995;7:1360-65
22. Rall JM, Mach SA, Dash PK. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res 2003;968:273-76
23. Shaw KN, Commins S, O'Mara SM. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broadspectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur J Neurosci 2003;17:2438-46
24. 2 signaling in hippocampal long-term synaptic activity. J Neurophysiol 2002;87:2851-57
25. Bazan NG. Synaptic lipid signaling: Significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res 2003;44: 2221-33
26. Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci 2000;20:763-70
27. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9
28. Martino G, Adorini L, Rieckmann P, et al. Inflammation in multiple sclerosis: The good, the bad, and the complex. Lancet Neurol 2002; 1:499-509
29. Matute C, Alberdi E, Domercq M, Perez-Samrtin A, Sanchez Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001;24:224-30
30. Alosi F, Serafini B, Adorini L. Glia-T cell dialogue. J Neuroimmunol 2000;107:111-17
31. Deininger MH, Schluesener HJ. Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol 1999;95:202-8
32. Minghetti L, Hughes P, Perry VH. Restricted cyclooxygenase-2 expression in the central nervous system following acute and delayed-type hypersensitivity responses to bacillus Calmette-Guerin. Neuroscience 1999;92:1405-15
33. Rose JW, Hill KE, Watt HE, Carlson NG. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol 2004;149:40-49
34. Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998;391: 281-85
35. Trotti D, Rossi D, Gjesdal O, et al. Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem 1996;271:5976-79
36. Harris SG, Padilla J, Koumas L, Ray D, Phipps RR Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50
37. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E. J Exp Med 1992;176:1355-64
38. Reder AT, Thapar M, Sapugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994;54:117-27
39. Fretland DJ. Related potential role of prostaglandins and leukotrienes in multiple sclerosis and experimental allergic encephalomyelitis. Prostaglandins Leukot Essent Fatty Acids 1992;45:249-57
40. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999;53:1876-79
41. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS - a dual role? Exp Neural 2004;187:1-10
42. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord: Implication for therapy. Neurology 2001;57:952-56
43. Almer G, Guegan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neural 2001;49:176-85
44. 2 in CSF from ALS patients. Neurology 2002;58:1277-79
45. Maihofner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundorfer B, Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003;18:1527-34
46. Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neural 2000;48:792-95
47. Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neural 2002;52:771-78
48. 2: The endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 2002;99:7367-72
49. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003;24:395-401
50. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000;95:425-32
51. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2000;966:245-52
52. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-78
53. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000;16:724-39
54. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003;4:103-12
55. 2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neural 2000;59:866-71
56. Walsh DT, Perry VH, Minghetti L. Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 2000;29:392-96
57. Minghetti L, Geloso MC, Sbricioli M, et al. Increased expression od cyclooxygenase-2 in murine models of prion diseases. (Abstract) Clin Neuropathol 2001;20:127
58. Deininger MH, Bekure-Nemariam K, Trautmann K, Morgalla M, Meyermann R, Schluesener HJ. Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease. J Mol Neurosci 2003;20:25-30
59. Minghetti L, Cardone F, Greco A, et al. Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology 2002;58:127-29
60. Gray F, Chretien F, Adle-Biassette H, et al. Neuronal apoptosis in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 199;58:321-28
61. De Simone R, Ajmone-Cat MA, Minghetti L. Atypical antiinflammatory activation of microglia induced by apoptotic neurons: Possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol Neurobiol 2004;29:197-212
62. Bate C, Rutherford S, Gravenor M, Reid S, Williams A. Cyclooxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport 2002;13:1933-38
63. Manuelidis L, Fritch W, Zaitsev I. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet 1998;352:456
64. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. The Lancet Neurology 2002;1:279-84
65. Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996;17:801-8
66. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87:319-24
67. Lukiw WJ, Bazan NG. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997;50:937-45
68. Yermakova AV, O'Banion MK. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 2001;22:823-36
69. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 2002;61:678-88
70. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Arendt T, Eikelenboom P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 2004;15:492-99
71. Nagy Z, Esiri MM, Smith AD. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 1998;87: 731-39
72. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer's, and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999;58:1135-46
73. Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999;53: 1495-98
74. Combrinck M, De Berardinis MA, Warden D, Williams J, Puopolo M, Minghetti L. Levels of cerebrospinal fluid prostaglandin E2 are mildly elevated in early Alzheimer's disease but decline with increasing severity of dementia. (Abstract) Brain Pathol 2003:S81